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Abstract
Introduction: Although pregnancy-related factors such as nulliparity and late age at first full-term pregnancy are well-
established risk factors for invasive breast cancer, the roles of these factors in the natural history of breast cancer 
development remain unclear.
Methods: Among 52,464 postmenopausal women participating in the California Teachers Study (CTS), 624 were 
diagnosed with breast carcinoma in situ (CIS) and 2,828 with invasive breast cancer between 1995 and 2007. 
Multivariable Cox proportional hazards regression methods were used to estimate relative risks associated with parity, 
age at first full-term pregnancy, breastfeeding, nausea or vomiting during pregnancy, and preeclampsia.
Results: Compared with never-pregnant women, an increasing number of full-term pregnancies was associated with 
greater risk reduction for both breast CIS and invasive breast cancer (both P trend < 0.01). Women having four or more 
full-term pregnancies had a 31% lower breast CIS risk (RR = 0.69, 95% CI = 0.51 to 0.93) and 18% lower invasive breast 
cancer risk (RR = 0.82, 95% CI = 0.72 to 0.94). Parous women whose first full-term pregnancy occurred at age 35 years or 
later had a 118% greater risk for breast CIS (RR = 2.18, 95% CI = 1.36 to 3.49) and 27% greater risk for invasive breast 
cancer (RR = 1.27, 95% CI = 0.99 to 1.65) than those whose first full-term pregnancy occurred before age 21 years. 
Furthermore, parity was negatively associated with the risk of estrogen receptor-positive (ER+) or ER+/progesterone 
receptor-positive (PR+) while age at first full-term pregnancy was positively associated with the risk of ER+ or ER+/PR+ 
invasive breast cancer. Neither of these factors was statistically significantly associated with the risk of ER-negative (ER-) 
or ER-/PR- invasive breast cancer, tests for heterogeneity between subtypes did not reach statistical significance. No 
clear associations were detected for other pregnancy-related factors.
Conclusions: These results provide some epidemiologic evidence that parity and age at first full-term pregnancy are 
involved in the development of breast cancer among postmenopausal women. The role of these factors in risk of in situ 
versus invasive, and hormone receptor-positive versus -negative breast cancer merits further exploration.
Introduction
Although pregnancy-related factors such as nulliparity
and late age at first full-term pregnancy are well-estab-
lished risk factors for invasive breast cancer, it remains
unclear whether such factors have similar effects on
breast carcinoma in situ (CIS) or whether their effects
vary across the subtypes of invasive breast cancer defined
by the estrogen receptor (ER) or the joint ER and proges-
terone receptor (PR) status of the tumor. The clarification
of these issues may shed light on a deeper understanding
of the roles of pregnancy-related factors in the natural
history of breast cancer development.
Breast CIS includes ductal carcinoma in situ (DCIS),
lobular carcinoma in situ (LCIS), and other relatively rare
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forms of breast CIS, with DCIS being the predominant
subtype. The term 'in situ' indicates that neoplastic cells
are present but have not spread past the boundaries of
ducts or lobules where the tumor initially developed.
Estimates of the percentage of patients with DCIS that
will progress to invasive disease over a period of 10 or
more years vary widely, ranging from 14 to 53% [1] and
likely depend on a variety of factors, including type and
extent of treatment and medical surveillance. Unlike
DCIS, LCIS indicates neoplastic changes in the breast
lobules, a precursor lesion that carries an elevated risk of
invasive lobular carcinoma in either breast; thus, it is not
included in clinical definitions of in situ breast cancer
[2,3]. In contrast, DCIS and other forms of breast CIS are
clinically considered pre-invasive lesions that can be
associated with the development of invasive breast cancer
at the same location in the breast where the CIS is
located. Nevertheless, epidemiologic studies have shown
that, compared with the general population, the risk of
invasive breast cancer increases over four-fold following a
diagnosis of either DCIS or LCIS [4,5].
Given that breast CIS is a potential precursor to inva-
sive disease, one would expect that breast CIS and inva-
sive breast cancer would share risk factors involved in the
early stages of breast cancer development while factors
affecting disease progression would be associated only
with invasive breast cancer risk. Few studies have made
direct comparisons of the consistency of risk estimates
for pregnancy-related risk factors between breast CIS and
invasive breast cancer within a study population, particu-
larly among women whose reproductive years have
ended. In studies that provided results for postmeno-
pausal women, parity was associated with a decreased
risk for both postmenopausal breast CIS and postmeno-
pausal invasive breast cancer; results for age at first full-
term pregnancy were inconsistent [6-8]. None of these
studies provided results on the effects of breastfeeding,
nausea or vomiting during pregnancy, or preeclampsia on
the risk of breast CIS or invasive breast cancer.
Parity, early age at first full-term pregnancy, and breast-
feeding influence the risk of breast cancer predominantly
through hormonal mechanisms that involve estrogen and
progesterone [9,10]. Previous studies have also linked
severe nausea/persistent vomiting during pregnancy to
elevated serum estradiol levels [11], and have shown that
preeclampsia is associated with lower maternal serum
levels of estriol [12] and insulin-like growth factors [13].
Therefore, severe nausea/persistent vomiting during
pregnancy might be associated with an increased risk
while preeclampsia might be associated with a decreased
risk of breast cancer. Although a number of epidemio-
logic studies have examined severe pregnancy nausea/
vomiting [14-16] or history of preeclampsia [17-23] in
relation to invasive breast cancer risk, the data have been
inconsistent for both factors. Further, no data have been
published specifically for breast CIS.
Both a systematic review [24] and a meta-analysis [25]
show that nulliparity and late age at first full-term preg-
nancy are associated with increased risk of ER-positive
(ER+) or ER+/PR+, but not with ER-negative (ER-) or ER-
/PR- invasive breast cancer. In contrast, the protection
from breastfeeding does not differ by ER/PR status. How-
ever, these results are based largely on results from case-
control studies and only a small number of these studies
provide data for postmenopausal women separately from
premenopausal women. Three prospective cohort studies
that have assessed reproductive factors in relation to hor-
mone receptor subtypes of invasive breast cancer provide
consistent results for parity, but inconsistent results for
late age at first full-term pregnancy. Further, no data are
given for the association of breastfeeding with the hor-
mone receptor subtypes of invasive breast cancer [26-28].
Thus, important questions remain regarding the roles
of pregnancy-related factors in the development of breast
CIS and invasive breast cancer among women who have
completed their reproductive years. The authors exam-
ined the associations of parity, age at first full-term preg-
nancy, duration of breastfeeding, nausea or vomiting
during pregnancy, and preeclampsia with breast CIS and
invasive breast cancer (overall and by hormonal receptor
subtype) among postmenopausal women participating in
the prospective California Teachers Study (CTS) cohort.
Materials and methods
Study population and data collection
Details of the CTS have been described previously [29].
Briefly, the CTS is a prospective study of 133,479 current
and retired female California public school teachers and
administrators who were recruited from active members
of the California State Teachers Retirement System. New
diagnoses of first primary breast CIS or invasive breast
cancer among cohort members were identified through
annual linkages from 1995 through 2007 with the Califor-
nia Cancer Registry (CCR), a legally mandated statewide
population-based cancer reporting system. Modeled after
the National Cancer Institute's Surveillance, Epidemiol-
ogy, and End Results (SEER) Program, the CCR is com-
posed of three SEER Program registries and maintains
the highest standards for data quality and completeness.
CCR ascertainment of newly diagnosed cancers is esti-
mated to be 99% complete [30].
All information on pregnancy-related factors except
nausea or vomiting during pregnancy and preeclampsia
was collected in the questionnaire completed by partici-
pants when they joined the cohort. Participants reported
information on race/ethnicity, family history of breast
cancer, age at menarche, detailed pregnancy (including
ages at and outcomes for each pregnancy) and breast-Ma et al. Breast Cancer Research 2010, 12:R35
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feeding histories, menopausal status, use of menopausal
hormone therapy, height, and weight. Participants
reported information regarding nausea or vomiting dur-
ing pregnancy and preeclampsia in the second question-
naire completed in 1997-1998. Preeclampsia was defined
as a condition that can occur during the second half of a
pregnancy and is marked by elevated blood pressure, pro-
tein in the urine and fluid retention.
For the current analysis, using information provided
when the cohort was formed, 8,867 women who were not
California residents were excluded, followed by 6,350
women who had a prior history of breast CIS or invasive
breast cancer or an unknown cancer history and by 5,107
women who were 80 years or older. This yielded a prelim-
inary analytic cohort of 113,155 women. In order to
ensure that each woman's complete pregnancy history
was covered, eligibility for this analysis was restricted to
women who were postmenopausal at cohort entry (n =
53,440). Menopausal status was determined after review-
ing a woman's age at last menstrual period, reason for
cessation of menstrual periods, hysterectomy status,
oophorectomy status and current use of hormonal ther-
a p y .  W o m e n  w e r e  c o n s i d e r ed  t o  be  po s t m e n o p a u s a l  i f
they reported a natural menopause more than six months
before completing the baseline questionnaire (n =
31,207), if they had a bilateral oophorectomy (n = 10,868),
if they were 56 years or older and not menstruating regu-
larly (n = 6,675), or if their periods had stopped due to
other reasons including pituitary adenoma, medication,
chemotherapy, radiation treatment, or another reason (n
= 4,690). The age criterion was based on previous work
indicating that among those with natural menopause 97%
were postmenopausal by age 56 years [31]. Further exclu-
sions were women who were missing information on age
at menarche (n = 217), pregnancy history (n = 75), or
both factors (n = 684). Therefore, 52,464 postmenopausal
women remained in the analytic cohort.
Person-time of follow-up for each woman began with
the date she completed the baseline questionnaire and
ended with the first of the following events: a breast can-
cer diagnosis (n = 624 breast CIS including 51 women
diagnosed with LCIS, ICD-O morphology code = 8520; n
= 2,828 invasive), a permanent move outside of California
(n = 4,481), death (n = 5,852), or December 31, 2007 (n =
38,679).
The analytic cohort included 8,937 never-pregnant and
43,527 ever-pregnant women. Of the 43,527 ever-preg-
nant women, 371 experienced pregnancy but did not pro-
vide outcome, and 1,957 had only incomplete
pregnancies. Women who experienced pregnancy and
did not provide an outcome and those who had only
incomplete pregnancies were included when testing the
effect of any pregnancy (ever vs. never), but were
excluded from analyses of parous women. The effect of
incomplete pregnancy on breast cancer risk has previ-
ously been studied in this cohort [32].
The 41,199 women who had at least one stillbirth or
live childbirth were referred to as parous throughout this
article. Still and live births were combined to obtain the
total number of full-term pregnancies. Parous women
who were missing information on breastfeeding or age at
first full-term pregnancy (n = 117) were additionally
excluded from analyses restricted to parous women.
Analyses of parous women were based on 41,082 women
of whom 479 were diagnosed with breast CIS and 2,193
were diagnosed with invasive breast cancer during fol-
low-up.
Of 43,527 ever-pregnant postmenopausal women at
cohort entry, 32,084 (73.7%; including 394 with breast
CIS and 1,794 with invasive breast cancer) provided
information on nausea or vomiting during any pregnancy
and 31,459 (72.3%; including 391 with breast CIS and
1,768 with invasive breast cancer) provided information
on preeclampsia in the CTS' second questionnaire, which
was mailed in 1997, and were included in the analysis of
these factors.
Since 1990, National Cancer Institute designated SEER
Program registries, including those comprising the CCR,
routinely abstract ER and PR status from the medical
records following a breast cancer diagnosis. Among 2,828
invasive breast cancers diagnosed in the current analytic
cohort, ER status was available for 2,443 (86.4%; 2,104
ER+, 339 ER-). Both ER status and PR status were avail-
able for 2,326 (82.2%; 1,651 ER+/PR+, 317 ER-/PR-, 340
ER+/PR-, 18 ER-/PR+).
The use of CTS participants' data for this analysis was
approved by the Institutional Review Boards at the City
of Hope, the University of Southern California, the Can-
cer Prevention Institute of California (formerly the
Northern California Cancer Center), and the University
of California at Irvine, and by the Committee for the Pro-
tection of Human Subjects, California Health and Human
Services Agency.
Data analyses
The relative hazard (represented as the relative risk (RR)
and its 95% confidence interval (CI)) for the association
between pregnancy-related factors and breast cancer risk
was estimated using multivariable Cox proportional haz-
ards regression methods [33]. Separate analyses were
conducted for breast CIS and invasive breast cancer (the
latter, overall and by hormone receptor subtypes: ER+
and ER-, ER+/PR+ and ER-/PR-).
For all analyses of breast CIS, women diagnosed with
invasive breast cancer during follow-up were excluded as
the diagnosis of invasive disease presumes they have
passed through the in situ disease stage undetected. For
analyses of invasive breast cancer, women who developedMa et al. Breast Cancer Research 2010, 12:R35
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breast CIS were censored on the date of this diagnosis.
For analyses of each receptor subtype of invasive breast
cancer, women who developed all other receptor sub-
types or had an unknown subtype were censored on the
date of this diagnosis.
In the Cox regression models, the time scale was
defined by age (in days) at cohort entry and age (in days)
at event or censoring (exit). All multivariable models
were adjusted for the following factors, selected a priori,
as potential confounders: race (white, African-American,
others), family history of breast cancer in a first degree
relative, that is, mother, father, sister or brother (yes, no,
unknown/adopted), age at menarche (< 13, ≥ 13 years),
menopausal hormone therapy (HT) use (never use, ever
use: only estrogen therapy (ET), only estrogen in combi-
nation with progesterone therapy (E+P), both types of
HT, unknown type of HT) and body mass index (< 25, 25
to 29.9, ≥ 30 kg/m2, unknown).
Multivariable models for parous women were addition-
ally mutually adjusted for number of full-term pregnan-
cies (1, 2, 3, ≥ 4), age at first full-term pregnancy (< 21, 22
to 24, 25 to 29, 30 to34, ≥ 35 years), and duration of
breastfeeding (never, < 6, 6 to 11, 12 to 23, ≥ 24 months).
The associations of breast CIS or invasive breast cancer
with nausea or vomiting during pregnancy or preeclamp-
sia were explored among postmenopausal women with at
least one pregnancy as reported at cohort entry who had
complete information on one or both of these variables in
the second mailed questionnaire. Nausea or vomiting
during any pregnancy was examined as was the number
of pregnancies during which the ever-pregnant woman
experienced these symptoms (1, 2, 3, ≥ 4) and whether
treatment was received for these symptoms during the
most recent pregnancy or during other pregnancies.
Preeclampsia was evaluated as never occurring during a
pregnancy, occurring during the most recent pregnancy,
or not occurring during the most recent pregnancy but
having occurred during at least one of other pregnancies.
Multivariable models for nausea or vomiting during preg-
nancy or preeclampsia were additionally adjusted for
pregnancy history (number of full-term pregnancies: 1, 2,
3, ≥ 4; ever pregnant but outcomes unknown; ever preg-
nant but no full-term pregnancy).
Tests for trend were conducted to examine the dose-
response relationship of breast CIS or invasive breast
cancer with number full-term pregnancies, age at first
full-term pregnancy, duration of breastfeeding, and num-
ber of pregnancies during which participant experienced
nausea or vomiting by fitting ordinal values correspond-
ing to each exposure category in the statistical models
and determining whether the slope parameter differed
from zero using the Wald test [34].
Tests for homogeneity (evaluating the null hypothesis
of homogeneity) of RR estimates were performed (for
dichotomous variables or ordinal variables) by construct-
ing a Z test of the differences in log RR divided by the
square root of the sum of the variances of the two log RR
estimates for the following comparisons: breast CIS vs.
invasive breast cancer, ER+ vs. ER-, and ER+/PR+ vs. ER-/
PR- breast cancer.
The analyses for breast CIS were repeated among
44,671 (90%) postmenopausal women who reported hav-
ing their most recent mammogram less than three years
before the CTS baseline survey. The results remained the
same. The analysis for breast CIS was also repeated after
excluding 51 women diagnosed with LCIS. Again, the
results remained essentially identical. The results for
breast CIS including LCIS from all postmenopausal
women without invasive breast cancer (n = 49,636) are
presented.
Two-sided P-values are reported for tests for trend and
for homogeneity of RR estimates. All statistical analyses
were performed using SAS version 9.1 (SAS Institute,
Cary, North Carolina, USA).
Results
Characteristics
Women in the analytic cohort were followed for an aver-
age of 10.5 years. Table 1 provides the age-adjusted distri-
bution of several participant characteristics according to
pregnancy history (never-pregnant, ever-pregnant), age
at first full-term pregnancy, and number of full-term
pregnancies. Compared with never-pregnant women,
those who had ever been pregnant were more likely to be
African-American women. Parous African-American
women were less likely than other women to have had
three or more full-term pregnancies with the first full-
term pregnancy at age 25 years or older. Parous women
who had more full-term pregnancies (≥ 3) were more
likely to have a longer duration of breastfeeding than
those who had fewer full-term pregnancies (< 3).
Parity, age at first full-term pregnancy and duration of 
breastfeeding
Compared with never-pregnant women, women who
experienced any pregnancy had reduced risks of breast
CIS (RR = 0.85, 95% CI = 0.69 to 1.04) and invasive breast
cancer (RR = 0.91, 95% CI = 0.83 to 1.00) (Table 2). Com-
pared with never-pregnant women, the magnitude of risk
reductions increased with increasing number of full-term
pregnancies for both breast CIS (P trend = 0.008) and
invasive breast cancer (P trend = 0.003).
In analyses restricted to parous women, increasing age
at first full-term pregnancy was associated with an
increased risk for both breast CIS and invasive breast
cancer (breast CIS, P trend = 0.09; invasive breast cancer,
P trend = 0.002) (Table 2). Women who had a first full-
term pregnancy at age 35 years or older had more than aMa et al. Breast Cancer Research 2010, 12:R35
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Table 1: Age-adjusteda percent distribution of baseline characteristics
Total Ever pregnant, % Parous women (number of full-term pregnancy/age at first 
full-term pregnancy, yrs), %
No Yes < 3/< 25 < 3/≥ 25 ≥ 3/< 25 ≥ 3/≥ 25
(n = 8,937) (n = 43,527) (n = 8,034) (n = 14,825) (n = 10,851) (n = 7,372)
Race
White 46,624 16.8 83.2 19.8 34.4 28.2 17.7
African-American 1,622 11.1 88.9 25.9 34.6 28.3 11.2
Others 4,218 17.2 82.8 17.7 36.0 27.9 18.4
First-degree family history of breast 
cancer
No 43,489 16.6 83.4 19.8 34.5 28.3 17.3
Yes 7,132 16.8 83.2 19.2 34.5 27.0 19.3
Unknown 1,843 17.8 82.2 20.8 35.7 27.7 15.9
Age at menarche, years
< 13 26,220 16.9 83.1 20.6 34.3 28.7 16.4
≥ 13 26,244 16.4 83.6 19.0 34.8 27.6 18.7
BMI, kg/m2
< 25 27,583 16.9 83.1 20.4 35.8 26.6 17.2
25 to 29.9 14,354 15.8 84.2 19.1 32.6 30.0 18.3
≥ 30 7,783 17.5 82.5 19.1 33.4 30.6 16.9
Unknown 2,744 16.0 84.0 18.7 35.6 26.7 19.0
Menopausal HT use
Never 10,945 20.4 79.6 16.0 35.5 27.3 21.2
E only 15,676 15.6 84.4 21.8 31.2 30.4 16.7
E plus P only 14,959 15.8 84.2 19.8 37.7 25.8 16.7
Mixed use 7,169 15.7 84.3 21.1 32.7 30.3 15.9
Unknown type of HT 3,715 15.2 84.8 19.8 35.7 26.7 17.8
Duration of breastfeeding for 
parous women, months
Never 12,628 - - 25.0 39.7 22.0 13.3
< 6 11,202 24.1 35.2 26.8 13.9
6 to 11 7,124 19.5 38.2 26.9 15.4
12 to 23 6,486 11.1 28.4 35.3 25.2
≥ 24 3,642 3.3 17.2 44.2 35.3
Results are for 52,464 postmenopausal women in the California Teachers Study followed between 1995 and 2007.aAge distribution in each 
category of the baseline characteristic variables was adjusted according to age distribution of the 52,464 participants. Abbreviations: BMI, body 
mass index; HT, hormone therapy; E, estrogen; P, progestin.Ma et al. Breast Cancer Research 2010, 12:R35
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Table 2: Adjusted RRs for the association between pregnancy-related factors and breast CIS and invasive breast 
cancer
Breast CIS Invasive breast cancer
Observed
Person-years
Cases No. Adjusted 
RR (95% CI)
Observed
Person-years
Cases No. Adjusted 
RR (95% CI)
All women
Ever pregnant
No 90,296 116 Reference 92,927 493 Reference
Yes 444,276 508 0.85 (0.69 to 1.04) 457,417 2335 0.91 (0.83 to 1.00)
P for homogeneitya 0.55
Number of full-term pregnanciesb
1 68,527 91 1.01 (0.77 to 1.33) 70,615 355 0.95 (0.83 to 1.09)
2 165,472 188 0.84 (0.67 to 1.06) 170,385 878 0.94 (0.84 to 1.04)
3 112,458 131 0.84 (0.65 to 1.08) 115,629 591 0.88 (0.78 to 0.99)
≥ 4 74,458 70 0.69 (0.51 to 0.93) 76,634 373 0.82 (0.72 to 0.94)
P trend 0.008 0.003
P for homogeneitya  0.26
Ever pregnant, incomplete pregnancies 
only or outcome of pregnancies 
unknown
23,361 28 24,154 138
Parous women onlyc, d
Number of full-term pregnancies
1 68,338 90 Reference 70,426 355 Reference
2 164,995 188 0.92 (0.70 to 1.20) 169,889 875 1.00 (0.88 to 1.14)
3 112,082 131 0.93 (0.69 to 1.26) 115,253 590 0.95 (0.82 to 1.10)
≥ 4 74,291 70 0.77 (0.54 to 1.11) 76,467 373 0.90 (0.77 to 1.07)
P trend 0.22 0.15
P for homogeneitya  0.61
Age at first full-term pregnancies, years
< 21 46,965 44 Reference 48,165 203 Reference
21 to 24 146,568 166 1.17 (0.84 to 1.63) 150,692 727 1.07 (0.92 to 1.25)
25 to 29 158,816 183 1.18 (0.84 to 1.66) 163,749 888 1.22 (1.05 to 1.43)
30 to 34 51,266 50 0.99 (0.65 to 1.50) 52,784 281 1.22 (1.01 to 1.47)
≥ 35 16,091 36 2.18 (1.36 to 3.49) 16,644 94 1.27 (0.99 to 1.65)
P trend 0.09 0.002
P for homogeneitya  0.82
Duration of breastfeeding, months
Never 127,851 151 Reference 131,753 688 Reference
< 6 113,869 132 0.97 (0.77 to 1.22) 117,111 571 0.94 (0.84 to 1.05)
6-11 73,115 82 0.93 (0.71 to 1.22) 75,315 402 1.05 (0.93 to 1.19)
12-23 67,172 79 1.03 (0.77 to 1.36) 69,112 352 1.02 (0.90 to 1.17)Ma et al. Breast Cancer Research 2010, 12:R35
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two-fold greater risk of breast CIS (RR = 2.18, 95% CI =
1.36 to 3.49), and 27% (RR = 1.27, CI = 0.99 to 1.65)
greater risk of invasive breast cancer compared with
women whose first full-term pregnancy was before age 21
years. In a model adjusted for age at first full-term preg-
nancy and number of full-term pregnancies, duration of
breastfeeding was not statistically significantly associated
with the risk of either breast CIS or invasive breast cancer
among parous women.
Further, the risk estimates for parity, age at first full-
term pregnancy, and breastfeeding did not differ statisti-
cally between breast CIS and invasive breast cancer (all P
for homogeneity > 0.25). In addition, these risk estimates
for both breast CIS and invasive breast cancer did not
vary within subgroups defined by body mass index (< 25,
≥ 25 kg/m2), HT use (never, ever use), and race (white,
others).
In the analyses for invasive breast cancer by ER status
and joint ER and PR status, ever being pregnant, having
multiple full-term pregnancies, and having an early age at
first full-term pregnancy were each statistically signifi-
cantly associated with reduced risk of ER + and of ER +/
PR + invasive breast cancer, and were not statistically sig-
nificantly associated with ER- or ER-/PR- invasive breast
cancer, but none of the tests for homogeneity of risk esti-
mates comparing results for ER+ to those for ER- or com-
paring those for ER +/PR + to those for ER -/PR - reached
statistical significance (Table 3). Duration of breastfeed-
ing was not statistically significantly associated with any-
one of ER +, ER -, ER+/PR +, and ER -/PR - invasive
breast cancer.
Nausea or vomiting during pregnancy
Among women who experienced any pregnancy, nausea
or vomiting during pregnancy was not associated with
risk of breast CIS or invasive breast cancer regardless of
the number of pregnancies in which it occurred (one or
more) or if the woman received treatment for nausea or
vomiting of pregnancy (a measure of severity of the con-
dition) or the timing of that treatment (for the most
recent or only for earlier pregnancies) (all 95% CIs
include 1, all P trend > 0.05; Table 4).
Preeclampsia
Among women who experienced any pregnancy, preec-
lampsia diagnosed during the most recent pregnancy was
associated with an increased risk of breast CIS (RR =
1.72, 95% CI = 1.05 to 2.81), but was not associated with
invasive breast cancer (Homogeneity test P = 0.06, Table
4). Preeclampsia diagnosed during any pregnancies prior
to the most recent was not statistically significantly asso-
ciated with either breast CIS risk (RR = 0.93, 95% CI =
0.53 to 1.62) or invasive breast cancer (RR = 0.77, 95% RR
= 0.58 to 1.02).
Discussion
In the CTS, nulliparity and late age at first full-term preg-
nancy were associated with higher risk for both breast
CIS and invasive breast cancer, although not all of the
associations with breast CIS reached statistical signifi-
cance, in part due to the lower incidence of breast CIS in
the cohort. Three previous studies have reported data on
both breast CIS and invasive breast cancer for women
beyond reproductive age [6-8]. In a cohort study of
32,607 postmenopausal women followed for approxi-
mately five years, nulliparous women had a 70% higher
risk of breast CIS and a 40% higher risk of invasive breast
cancer than women who had a full-term pregnancy
before age 21 years; the same study showed that later age
at first full-term pregnancy was associated with an
increased risk of invasive breast cancer, but was not sta-
tistically significantly associated with breast CIS risk [8].
The Iowa Women's Health Study whose 37,105 post-
menopausal participants were followed for 11 years
found that women with late age at first birth (≥ 30 years)
had a 92% and a 29% greater risk for DCIS and invasive
breast cancer, respectively, than women whose first birth
occurred at or before age 20 years [6]. One previous pop-
ulation-based case-control study also reported that
parous postmenopausal women had decreased risk of
both breast CIS and invasive breast cancer relative to nul-
≥ 24 37,699 35 0.87 (0.59 to 1.29) 38,744 180 0.99 (0.84 to 1.18)
P trend 0.70 0.56
P for homogeneitya  0.56
RRs are from multivariable Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with 
the adjustment for race, family history of breast cancer in a first degree relative, age at menarche, HT use, body mass index. aHomogeneity in risk 
estimates between breast CIS and invasive breast cancer. bCompared with nulligravid women. cAdditionally, number of full-term pregnancies, 
age at first full-term pregnancy, and duration of breastfeeding mutually adjusted among parous women. dAdditionally excluded parous women 
who were missing information on breastfeeding or age at first full-term pregnancy. Abbreviations: CIS, carcinoma in situ; RR, relative risk; CI, 
confidence interval; HT, hormone therapy.
Table 2: Adjusted RRs for the association between pregnancy-related factors and breast CIS and invasive breast 
cancer (Continued)M
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Table 3: Adjusted RRs for the association between pregnancy-related factors and the subtypes of invasive breast cancer
ER+ ER- ER+/PR+ ER-/PR-
Cases No. Adjusted RR (95% CI) Cases No. Adjusted RR (95% CI) Cases No. Adjusted RR (95% CI) Cases No. Adjusted RR (95% CI)
All women
Ever pregnant
No 382 Reference 56 Reference 318 Reference 50 Reference
Yes 1,722 0.87 (0.78 to 0.97) 283 0.99 (0.74 to 1.31) 1,333 0.81 (0.71 to 0.91) 267 1.04 (0.77 to 1.41)
P for homogeneitya 0.42 0.12
Number of full-term pregnancyb
1 272 0.93 (0.80 to 1.09) 33 0.78 (0.51 to 1.20) 218 0.90 (0.75 to 1.06) 32 0.85 (0.55 to 1.33)
2 640 0.88 (0.77 to 1.00) 121 1.15 (0.84 to 1.58) 485 0.80 (0.69 to 0.92) 111 1.19 (0.85 to 1.66)
3 443 0.85 (0.74 to 0.98) 66 0.88 (0.62 to 1.26) 352 0.82 (0.70 to 0.95) 66 0.99 (0.68 to 1.43)
≥ 4 267 0.76 (0.65 to 0.89) 45 0.90 (0.61 to 1.34) 206 0.71 (0.59 to 0.85) 40 0.90 (0.59 to 1.37)
P trend 0.0004 0.72 < 0.0001 0.85
P for homogeneitya 0.33 0.17
Ever pregnant, incomplete pregnancies 
only or outcome of pregnancies unknown
100 18 72 18
Parous women onlyc, d
Number of full-term pregnancies
1 272 Reference 33 Reference 218 Reference 32 Reference
2 638 0.96 (0.83 to 1.11) 121 1.51 (1.01 to 2.25) 484 0.91 (0.77 to 1.08) 111 1.39 (0.92 to 2.10)
3 443 0.95 (0.80 to 1.12) 65 1.18 (0.75 to 1.86) 352 0.95 (0.79 to 1.15) 65 1.17 (0.74 to 1.85)
≥ 4 267 0.85 (0.70 to 1.04) 45 1.24 (0.75 to 2.07) 206 0.84 (0.68 to 1.05) 40 1.08 (0.64 to 1.83)
P trend 0.13 0.99 0.25 0.74
P for homogeneitya 0.57 0.87
Age at first full-term pregnancy, years
< 21 152 Reference 22 Reference 120 Reference 21 Reference
21 to 24 527 1.04 (0.87 to 1.25) 97 1.37 (0.86 to 2.18) 413 1.04 (0.85 to 1.28) 90 1.31 (0.81 to 2.12)M
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25 to 29 660 1.21 (1.01 to 1.45) 98 1.31 (0.82 to 2.10) 501 1.18 (0.97 to 1.45) 93 1.28 (0.79 to 2.07)
30 to 34 204 1.17 (0.94 to 1.46) 39 1.71 (0.99 to 2.95) 166 1.23 (0.96 to 1.57) 37 1.66 (0.95 to 2.90)
≥ 35 77 1.37 (1.02 to 1.83) 8 1.21 (0.52 to 2.81) 60 1.36 (0.98 to 1.89) 7 1.07 (0.44 to 2.60)
P trend 0.004 0.23 0.009 0.30
P for homogeneitya 0.96 0.92
Duration of breastfeeding, months
Never 499 Reference 80 Reference 379 Reference 75 Reference
< 6 433 0.98 (0.86 to 1.11) 68 0.97 (0.70 to 1.34) 346 1.03 (0.89 to 1.19) 63 0.96 (0.69 to 1.34)
6 to 11 296 1.06 (0.92 to 1.23) 52 1.15 (0.81 to 1.63) 229 1.08 (0.91 to 1.27) 50 1.16 (0.81 to 1.67)
12 to 23 259 1.04 (0.89 to 1.21) 42 1.02 (0.69 to 1.50) 205 1.08 (0.90 to 1.29) 39 1.02 (0.69 to 1.52)
≥ 24 133 1.02 (0.83 to 1.25) 22 1.00 (0.61 to 1.66) 101 1.00 (0.80 to 1.27) 21 1.06 (0.64 to 1.78)
P trend 0.52 0.78 0.54 0.65
P for homogeneitya 0.98 0.88
RRs are from multivariable Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with the adjustment for race, family history of breast 
cancer in a first degree relative, age at menarche, HT use, body mass index. aHomogeneity in risk estimates between subtypes of invasive breast cancer. bCompared with nulligravid women. 
cAdditionally, number of full-term pregnancies, age at first full-term pregnancy, and duration of breastfeeding mutually adjusted among parous women. dAdditionally excluded parous women who 
were missing information on breastfeeding or age at first full-term pregnancy. Abbreviations: RR, relative risk; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HT, hormone 
therapy.
Table 3: Adjusted RRs for the association between pregnancy-related factors and the subtypes of invasive breast cancer (Continued)M
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Table 4: Adjusted RRs for the association between pregnancy-related conditions and breast CIS and invasive breast cancer
Breast CIS Invasive breast cancer
Observed Person-years Cases No. Adjusted RR
 (95% CI)
Observed Person-years Cases No. Adjusted RR (95% CI) P for 
homogeneityb
Nausea or vomiting during pregnancy
Ever experienced
No 108,269 124 Reference 111,618 620 Reference
Yes 224,001 270 1.05 (0.85 to 1.30) 230,499 1,174 0.92 (0.84 to 1.02) 0.29
Number of pregnancies during which 
participant experienced nausea or 
vomitinga
1 73,892 84 0.92 (0.70 to 1.22) 75,959 380 0.91 (0.80 to 1.03)
2 72,819 95 1.21 (0.91 to 1.61) 75,015 387 0.94 (0.82 to 1.07
3 43,520 53 0.99 (0.70 to 1.41) 44,783 238 0.94 (0.80 to 1.11)
≥ 4 33,770 38 1.16 (0.76 to 1.77) 34,742 169 0.91 (0.75 to 1.11)
P trend 0.37 0.25 0.20
Ever needed treatment for nausea or 
vomiting during pregnancya
No 184,207 220 1.04 (0.83 to 1.30) 189,367 947 0.90 (0.81 to 1.00) 0.26
Yes, for most recent pregnancy 19,436 24 1.09 (0.70 to 1.69) 20,092 114 1.07 (0.88 to 1.31) 0.96
Yes, for other pregnancy(ies) 20,358 26 1.14 (0.74 to 1.74) 21,039 113 1.01 (0.83 to 1.24) 0.63
Preeclampsia
Ever diagnosed with preeclampsia
No 304,969 361 Reference 314,176 1673 Reference
Yes, during most recent pregnancy 8,431 17 1.72 (1.05 to 2.81) 8,699 44 0.98 (0.73 to 1.33) 0.06
Yes, during other pregnancy(ies) 12,379 13 0.93 (0.53 to 1.62) 12,648 51 0.77 (0.58 to 1.02) 0.57
RRs for gravid postmenopausal women based on multivariable Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with the adjustment 
for race, family history of breast cancer in a first degree relative, age at menarche, HT use, body mass index, pregnancy history (number full-term pregnancies: 1; 2; 3; ≥ 4; ever pregnant, but unknown 
whether full-term; ever been pregnant, but not full-term pregnancy). aCompared with gravid postmenopausal women who had never experienced nausea or vomiting during pregnancy. 
bHomogeneity in risk estimates between breast CIS and invasive breast cancer. Abbreviations: CIS, carcinoma in situ; RR, relative risk; CI, confidence interval; HT, hormone therapyMa et al. Breast Cancer Research 2010, 12:R35
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liparous women while late age at first full-term pregnancy
was not associated with either breast CIS or invasive
breast cancer [7]. Although the associations of parity and
age at first full-term pregnancy with risk of breast CIS
and invasive breast cancer have not been entirely consis-
tent across epidemiologic studies, as a whole, the data
provide some evidence that these two factors are involved
in the early stages of breast cancer development.
The mechanisms underlying the protective effect of
early parity on breast cancer are not yet clear. Mouse
models have demonstrated that breast carcinogenesis is
significantly inhibited when rats have completed one
pregnancy prior to exposure to the carcinogen compared
with age-matched virgin rats [35,36]. This protective
effect may be attributed to permanent structural and
functional changes induced in the mammary parenchyma
by the reproductive process, including exposure to preg-
nancy hormones, resulting in a lower susceptibility of
epithelial cells to future carcinogenic stimuli [37,38].
Moreover, rat gene expression data suggest that persis-
tent pregnancy-induced changes in mammary gene
expression may account for the protection of parity [39].
Human data suggest that hormonal mechanisms are
involved in pregnancy-related protection against breast
cancer including lowered circulating estrogen and pro-
gesterone [40-42], higher levels of sex hormone-binding
globulin [40] and possibly, human chorionic gonadotro-
pin [43], which has also been demonstrated in a rat car-
cinogenesis model [44].
In the CTS analyses for invasive breast cancer by hor-
mone receptor subtype, nulliparity and late age at first
full-t erm pregnancy were associa t ed wit h an incr eased
risk of ER + or ER +/PR + invasive breast cancer but not
with ER - or ER -/PR - invasive cancer. These are essen-
tially consistent with the conclusions of a systematic
review [24] and a meta-analysis [25], both consisting
largely of case-control studies. Compared with data from
previous cohort studies, the CTS results for both parity
and age at first full-term pregnancy are basically consis-
tent with those reported for the Iowa Women's Health
Study [28] and Women's Health Initiative Cohort [26],
but the CTS results for age at first full-term pregnancy
are inconsistent with those reported for the Nurses'
Health Study, in which late age at first full-term preg-
nancy was associated with an increased risk of ER -/PR -
but not ER +/PR +, tumors [27]. Therefore, similar to the
majority of previous data, these results support the
hypothesis that some pregnancy-related risk factors may
differentially influence risk for breast cancer subtypes
classified by ER and PR status.
Breastfeeding has been proposed to protect against
breast cancer through hormonal mechanisms that
include postponing the resumption of ovulatory men-
strual cycles after a pregnancy [45], reducing estrogen
levels in the breast [46], and having fully differentiated
breast tissue which is less susceptible to the hormone
milieu [47]. In addition, it has been proposed that breast-
feeding also has a direct mechanical effect by which car-
cinogenic agents are excreted from the breast ductal
tissue [48]. However, among parous postmenopausal CTS
participants, breastfeeding was not associated with either
breast CIS or invasive breast cancer (overall or by recep-
tor subtypes). The observed reductions in breast cancer
risk in many previous studies have been stronger for or
restricted to younger or premenopausal women
[10,15,49-52]. However, in some studies, this reduction in
risk was observed in the postmenopausal years [53-55] or
was negligible in both age groups [56,57]. Two studies
found that the protective effect of breastfeeding
decreased with the increasing time after a pregnancy
[15,58]. Among the parous women ages 35 to 49 year who
participated in Women's Contraceptive and Reproductive
Experiences study, the odds ratio (95% CI) of invasive
breast cancer associating with at least 24-month breast-
feeding was 0.38 (0.19 to 0.77) among women who had
given birth within five years and 0.69 (0.51 to 0.93) among
those beyond five years [58]. Among postmenopausal
CTS participants, the average interval between the last
pregnancy and CTS baseline survey was 32 years, and
only 1% of the intervals were within 15 years. Fine stratifi-
cation of the interval between the last pregnancy and
CTS baseline survey still did not show any association
between breastfeeding and breast cancer risk (results not
shown). Therefore, the lack of an association between
breastfeeding and breast cancer in the CTS analyses may
be due to the restriction to postmenopausal women.
Since hyperemesis gravidarum, that is, severe nausea
combined with persistent vomiting during pregnancy, has
been linked to an elevated serum estradiol level [11], one
might expect a positive association between these events
and the risk of breast CIS or invasive breast cancer. Being
treated served as a proxy for severe nausea or vomiting of
pregnancy, with not treated serving as a proxy for mild/
moderate symptoms. However, no association was
observed by severity of nausea or vomiting. Consistent
with these results, a population-based case-control study
h a s  a l s o  r e p o r t e d  n o  a s s o c i a t i o n  o f  b r e a s t  c a n c e r  r i s k
overall or by age (< 50, ≥ 50) with hyperemesis gravi-
darum [14]. In contrast with the results presented here,
one case-control study reported that having ever been
treated for nausea or vomiting during pregnancy was
associated with an increased risk of breast cancer [15]
while another case-control study reported that nausea or
vomiting during first pregnancy was associated with a
s l i g h t l y  l o w e r  ris k  o f  b r e as t  ca n c e r  [ 1 6 ] .  Bo t h  o f  t h e se
studies were conducted among young women (< 45 years
of age). It is possible that the null results from the CTS
study are due to an older population of women, or thatMa et al. Breast Cancer Research 2010, 12:R35
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the impact of this condition or the hormonal changes
related to it, dissipates with time since the pregnancy.
Preeclampsia has been associated with lower maternal
serum levels of estriol [12] and insulin-like growth factors
[13]. Therefore, preeclampsia might be associated with a
lower breast cancer risk. However, among postmeno-
pausal women in the CTS, preeclampsia diagnosed dur-
ing a woman's most recent pregnancy was associated
with an increased risk of breast CIS, while preeclampsia
diagnosed during any pregnancies prior to the most
recent was not associated with breast CIS risk. Preec-
lampsia was not associated with invasive breast cancer.
Although a number of epidemiologic studies have exam-
ined history of preeclampsia in relation to invasive breast
cancer risk, none have reported data specifically for
breast CIS. Among cohort studies reporting results for
preeclampsia and invasive breast cancer, one found a 38%
(95% CI = 1.00 to 1.89) greater risk of invasive breast can-
cer among women who ever experience preeclampsia
than among women with no such history [17], while
another reported that women with preeclampsia and/or
hypertension diagnosed during their first pregnancies
had 19% (95% CI = 0.71 to 0.91) lower risk for breast can-
cer than women who had not experienced preeclampsia
[18]. A third cohort study reported no association [19]. In
contrast, several case-control studies have reported that
preeclampsia was associated with a decreased risk of
breast cancer [20-23]. Based on the CTS results and those
of earlier studies, no conclusion can be drawn as to
whether preeclampsia is a risk factor for breast cancer.
Strengths of the current study include its size, the large
number of women who have been diagnosed with an
incident breast cancer, the ability to identify and confirm
cancer diagnoses through the CCR, California's high-
quality statewide cancer registry, and collection of preg-
nancy-related information prior to the diagnosis of breast
CIS or invasive breast cancer.
Several limitations of the current study must be consid-
ered. ER and PR status results were collected by the
regional registries in California from pathology laborato-
ries located throughout the state; these laboratories may
vary in their application of immunohistochemical meth-
ods and the cutpoints used to assign a positive status.
However, it is unlikely that any methodological differ-
ences would influence the observed associations, as a
large validation study comparing registry reports of
receptor status to those of a single expert  laboratory
found only small differences in risk estimates for ER+/
PR+ and ER-/PR- breast cancer between the two sources
[59]. Although not all women with invasive breast cancer
had ER or PR status available, the numbers missing this
information were relatively small (14% of cases missing
ER status; 18% missing joint ER and PR status), and the
percentage of women with missing information gradually
decreased during follow-up, both of which are similar to
the rates presented in previous studies conducted within
SEER registries [60,61]. Women with invasive breast can-
cer who had ER status available in the CCR had preg-
nancy-related factors (ever pregnant, number of full-term
pregnancies, age at first full-term pregnancy, and dura-
tion of breastfeeding) that were similar to those of
women who were missing ER status information (all
Pearson's chi-square P > 0.07). These pregnancy-related
factors were also similar between women having invasive
breast cancer who had information on both receptor sta-
tus markers and those without this information, except
that those with the information for both ER and PR status
were slightly more likely to have never been pregnant
(18.1% vs. 14.1%, Pearson's chi-square P = 0.03). This dif-
ference could cause an overestimate of any protective
effect of pregnancies on all subtypes, but it is unlikely that
this bias would be restricted to ER+/PR+ invasive breast
cancer. In addition, the relative risk estimates for ER+/
PR+ subtype differed minimally from those for ER+ sub-
type and the estimates for ER-/PR- subtype were similar
to those for ER- subtype. Therefore, the missing informa-
tion on ER and/or PR status is unlikely to have introduced
measurable bias in this study. Since 75% of women with
breast CIS had no data for ER/PR status, we were unable
to examine the association between pregnancy-related
factors and the risk of breast CIS by ER/PR status.
Another limitation is that the analyses for nausea or
vomiting during pregnancy and preeclampsia were based
on approximately 73% of ever-pregnant postmenopausal
women. These women were similar to those without
information on these two factors in terms of race, family
history of breast cancer in a first degree relative, age at
menarche, HT use, body mass index, number of full-term
pregnancy, age at first full-term pregnancy, and duration
of breastfeeding. Therefore, selection bias is unlikely to
be an important explanation for the results for these two
factors.
Conclusions
These results provide some epidemiologic evidence that
parity and age at first full-term pregnancy are involved in
the development of breast cancer among postmenopausal
women. This study did not provide evidence of any asso-
ciation of breastfeeding with postmenopausal diagnosis
of breast CIS or invasive breast cancer overall or by hor-
mone receptor subtypes. Further, nausea or vomiting
during pregnancy was not associated with stage of breast
cancer and no evidence was observed that preeclampsia
is clearly associated with lower breast cancer risk.
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